In the BioHarmony Drug Report Database

"Preview" Icon

Rotigotine

Neupro, Leganto (rotigotine) is a small molecule pharmaceutical. Rotigotine was first approved as Neupro on 2006-02-15. It is used to treat parkinson disease and restless legs syndrome in the USA. It has been approved in Europe to treat parkinson disease and restless legs syndrome. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target D(1B) dopamine receptor, D(4) dopamine receptor, D(3) dopamine receptor, and D(1A) dopamine receptor. Neupro’s patents are valid until 2032-03-01 (FDA).

 

Trade Name

 

Leganto, Neupro
 

Common Name

 

rotigotine
 

ChEMBL ID

 

CHEMBL1303
 

Indication

 

parkinson disease, restless legs syndrome
 

Drug Class

 

Image (chem structure or protein)

Rotigotine structure rendering